Effects of ammonia solution on the gastric mucosa in cirrhotic rats and therapeutic effects of geranylgeranylacetone

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 6, 1999, Pages 529-533

  Sugimoto, Motonobu ^a   Machida, Yota ^a   Ito, Kinji ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ammonia; Gastric mucosal defensive mechanism; Gastric mucosal lesion; Geranylgeranylacetone; Helicobacter pylori; Hexosamine; Liver cirrhosis

Indexed keywords

AMMONIA; CARBON TETRACHLORIDE; HEXOSAMINE; IRRITANT AGENT; TEPRENONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GASTRODUODENAL ULCER; HELICOBACTER PYLORI; HISTOPATHOLOGY; LIVER CIRRHOSIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; STOMACH CONTENT; STOMACH MUCOSA; STOMACH MUCOSA LESION;

EID: 0032975363     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01910.x     Document Type: Article

References (27)

1. 1 Kirk AP, Dooley JS, Hunt RH. Peptic ulceration in patients with chronic liver disease. Dig. Dis. Sci. 1980; 25: 756-60.
2. 2 Sacchetti C, Capello M, Rebecchi P et al. Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Dig. Dis. Sci. 1988; 33: 1218-22.
3. 3 Ostrow JD, Timmerman RJ, Gray SJ. Gastric secretion in human hepatic cirrhosis. Gastroenterology 1960; 38: 303-13.
4. 4 Scobie BA, Summerskill WH. Reduced gastric acid output in cirrhosis: Quantitation and relationships. Gut 1964; 5: 422-8.
5. 5 Lam SK. Hypergastrinemia in cirrhosis of the liver. Gut 1976; 17: 700-8.
6. 6 Gaur SK, Vij JC, Sarin SK, Anand BS. Gastric secretion in cirrhosis and non-cirrhotic portal fibrosis. Digestion 1988; 39: 151-5.
7. 7 Imoto I, Yoshida M, Shida Y, Watanabe S, Suzuki S. Campylobacter pylori infection and gastric mucosal lesions in patients with chronic liver disease. J. Gastroenterol. Hepatol. 1989; 1 (Suppl.): 75-7.
8. 8 Parikh SS, Desai SB, Prabhu SR et al. Congestive gastropathy: Factors influencing development, endoscopic features, Helicobacter pylori infection, and microvessel changes. Am. J. Gastroenterol. 1994; 89: 1036-42.
9. 9 Chen JJ, Changchien CS, Tai DI, Chiou SS, Lee CM, Kuo CH. Role of Helicobacter pylori in cirrhotic patients with peptic ulcer. A serological study. Dig. Dis. Sci. 1994; 39: 1565-8.
10. 10 Calvet X, Navarro M, Gil M et al. Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. J. Hepatol. 1997; 26: 1249-54.
11. 11 Makino H. A study of the pathogenesis of gastric mucosal lesions in patients with liver cirrhosis: With special reference to the gastric mucosal hexosamine and Helicobacter pylori. J. Med. Soc. Toho 1992; 38: 720-8 (in Japanese).
12. 12 Karita M, Kouchiyama T, Okita K, Kanazawa T. New small animal model for human gastric Helicobacter pylori infection: Success in both nude and euthymic mice. Am. J. Gastroenterol. 1991; 86: 1596-602.
13. 13 Hazell SL, Borody TJ, Gal A, Lee A. Campylobacter pyloridis gastritis. Am. J. Gastroenterol. 1987; 82: 292-6.
14. 14 Lichtenberger LM, Dial EJ, Romero JJ, Lechago J, Jarboe LA, Wolfe MM. Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology 1995; 108: 320-9.
15. 15 Kohli Y, Hata M, Yamazaki Y, Iwaki M, Kato T. Effects of 0.02% NH, solution and teprenone diet on acetic acid ulcer in rat stomachs. J. Kyoto Pref. Univ. Med. 1991; 100: 637-44.
16. 16 Neuhaus OW, Letzring M. Determination of hexosamines in conjunction with electrophoresis on starch. Anal. Chem. 1957; 29: 1230-3.
17. 17 Iwao T, Toyonaga A, Ikegami M, Shigemori H et al. Gastric mucus generation in cirrhotic patients with portal hypertension: Effects of tetraprenylacetone. Dig. Dis. Sci. 1996; 41: 1727-32.
18. 18 Muller A, Machnik F, Zimmermann T et al. Thioacetamide induced cirrhosis-like lesions in rats. Usefulness and reliability of this animal model. Exp. Pathol. 1988; 34: 299-306.
19. 19 Kawano S, Tanimura H, Tsuji S et al. Gastric mucosal energy metabolism and intracellular mucin content changes in patients with liver cirrhosis. J. Gastroenterol. Hepatol. 1996; 11: 380-4.
20. 20 Kunisaki C, Sugiyama M. Effect of teprenone on acute gastric mucosal lesions induced by cold-restraint stress. Digestion 1992; 53: 45-53.
21. 21 Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T. Anti-ulcer effect of geranylgeranylacetone, a new acyclic polyisoprenoid on experimentally induced gastric and duodenal ulcers in rats. Arzneimittelforschung 1981; 31: 799-804.
22. 22 Oketani K, Murakami M, Fujisaki H, Wakabayashi T, Effect of geranylgeranylacetone on aspirin-induced changes in gastric glycoproteins. Jpn. J. Pharmacol. 1983; 33: 593-601.
23. 23 Terano A, Shiga J, Hiraishi H, Ohta S, Sugimoto T. Protective action of tetraprenylacetone against ethanol-induced damage in rat gastric mucosa. Digestion 1986; 35: 182-8.
24. 24 Terano A, Hiraishi H, Ohta S, Sugimoto T. Geranylgeranylacetone, a novel anti-ulcer drug, stimulates mucus synthesis and secretion in rat gastric cultured cells. Digestion 1986; 33: 206-10.
25. 25 Nishizawa Y, Sakurai H, Oketani K, Horie T, Yamoto C, Moriga M. Effects of taurocholic acid/HCl alone or after pretreatment with geranylgeranylacetone on phospholipid metabolism in rat gastric mucosa. Biochem. Pharmacol. 1987; 23: 4111-17.
26. 26 Bilski J, Murty VLN, Nadziejko C et al. Protection against alcohol-induced gastric mucosal injury by geranylgeranylacetone: Effect of indomethacin. Digestion 1988; 41: 22-33.
27. 27 Hirayama T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996; 111: 345-57.